Sanofi wins $226m in funds to expand influenza vaccine capacity in US
Category: #headlines  By Saipriya Iyer  Date: 2019-12-10
  • share
  • Twitter
  • Facebook
  • LinkedIn
Sanofi wins $226m in funds to expand influenza vaccine capacity in US
  • The agreement is supported by federal funds from BARDA
     
  • A new manufacturing unit is to be established to facilitate sustainable production

France based pharmaceutical company- Sanofi Pasteur has reportedly signed an agreement with the U.S. Department of Health and Human Services to increase the production capacity of company’s domestic pandemic influenza vaccines in Swiftwater, Pennsylvania.

The agreement is supported by federal funds received from the Biomedical Advance Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at HHS.

According to David Loew, Executive Vice President of Vaccines at Sanofi, the contract will allow the company to enhance the supply of flu vaccines under cases of pandemic influenza. Sanofi Pasteur is focusing on advancing influenza vaccine technology along with enhancing the manufacturing mechanism, the public-private partnership will furthermore help safeguard people from influenza, he added.

Apparently, the agreement will foster clinical development and manufacturing of a recombinant pandemic vaccine to prepare the world for a global pandemic situation. The investigational pandemic vaccine will use the same technology as that of Flublok® Quadrivalent – an influenza vaccine developed by Sanofi.  

Moreover, the contract will enlarge the company’s role as a leading solution for pandemic preparedness by adding both adjuvant and recombinant manufacturing along with the prevailing egg-based manufacturing technique.

For the record, Flublok Quadrivalent may be given to adults above the age of 18 and is proven to prevent more than 30% to 43% confirmed cases of the infection in people who are 50 years old and above, as compared to its alternate vaccine.

Flublok Quadrivalent is the sole and effective protein-based influenza treatment solution which is approved by the U.S. Food and Drug Administration (FDA), rendering a precise genetic match of hemagglutinin (HA) from each suggested vaccine virus. HA is primarily a protein that is key to stimulating immunity to influenza.  

Sanofi is a global biopharmaceutical firm that primarily focuses on providing support to people through their health challenges. The company aims at preventing illness with the help of vaccines, providing advanced treatment techniques to fight pain and reduce suffering.

 

Source Credits: http://www.news.sanofi.us/2019-12-09-Sanofi-awarded-226-million-by-US-government-to-expand-pandemic-influenza-preparedness

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

Sequitur Labs officially joins the NVIDIA Partner Network
Sequitur Labs officially joins the NVIDIA Partner Network
By Saipriya Iyer

Sequitur Labs, a seminal technologies and solutions developer, has reportedly announced that it joined the NVIDIA Partner Network, an innovative platform of the renowned visual computing solutions provider, with complete support for the NVIDIA Jetson...

American Equity & Brookfield Asset Management ink new partnership deal
American Equity & Brookfield Asset Management ink new partnership deal
By Saipriya Iyer

American Equity Investment Life Holding Company, a renowned and leading US based life insurance firm, has reportedly announced a new strategic collaboration with a top Canadian alternative asset management firm, Brookfield Asset Management. The compa...

Arrival to set up its first U.S. EV factory in South Carolina
Arrival to set up its first U.S. EV factory in South Carolina
By Saipriya Iyer

Arrival, a London based electric vehicle (EV) manufacturer, has reportedly announced that it would be building its first U.S-based micro factory in York County of South Carolina. The company plans to initiate production operations at the facility dur...